Frontlight ResearchEarly access
Taking peoplePhase 2
Anakinra in Cerebral haemorrhage to Target secondary Injury resulting from Neuroinflammation - a phase II clinical trial
Key facts
- Who runs it
- Stichting Radboud universitair medisch centrum
- Where
- Netherlands3 sites in 1 countryChoose a country to see its sites
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 75 people, planned
- Started
- 28 Oct 2024
- Planned end
- 30 Sept 2025
- Type of study
- Interventional
- Record updated
- 28 October 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Age ≥ 18 years
- Supratentorial non-traumatic ICH confirmed by CT, without a confirmed causative lesion on admission CT-angiography (e.g. aneurysm, AVM, DAVF, cerebral venous sinus thrombosis) or other known underlying lesion (e.g. tumour, cavernoma)
- Minimal intracerebral haemorrhage volume of 10 mL
- Intervention can be started within 8 hours from symptoms onset
- Patient's or legal representative's informed consent
Who cannot take part
- Known prior allergic reaction to gadolinium contrast or one of the constituents of its solution for administration
- Live vaccinations within the last 10 days prior to this ICH
- Use of immunosuppressive or immune-modulating therapy at admission
- Known allergy to anakinra or other products that are produced by DNA technology using the micro-organism E. coli
- Known active malignancy
- Severe infection at admission, requiring antibiotic treatment
- Known active tuberculosis or active hepatitis
- Pre-stroke modified Rankin Scale score ≥ 3
- Severe renal impairment (eGFR <30ml/min/1.73m)
- Neutropenia (Absolute Neutrophil Count (ANC) <1.5 x 109/L )
- Severe ICH, unlikely to survive the first 72 hours (defined as Glasgow Coma Scale score < 6 at time of consent)
- Standard contraindications to MRI
- Confirmed or suspected haemorrhagic transformation of an arterial or venous infarct
- Planned neurosurgical haematoma evacuation
- Pregnancy or breast-feeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To determine the effect of high-dose versus low-dose anakinra compared to standard medical management on cerebral oedema development after spontaneous supratentorial intracerebral haemorrhage.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 28 October 2024